Figure 7.

Drug response signature-based combination chemotherapy. (A) Connectivity-MAP analysis identifies potential therapeutic drugs targeting OR signatures in PDO’s. Enrichment scores from searches using gene sets identified by GSEA and LOOCV/LR models are shown. (B) Response to oxaliplatin-based combination therapy in OR PDOs. Bar graphs show the IC₅₀ and Emax of each PDO towards oxaliplatin alone or in combination with imatinib, DAPT, irinotecan, mitomycin-C, mycophenolate mofetil, vorinostat, trichostatin-A, or Scriptaid at designated dosage. IC₅₀ is shown in relation to the IC₅₀ of oxaliplatin alone. For MMC and scriptaid, IC₁₀ was used for PDOs which were particularly sensitive to the drugs, and IC₃₀ or IC₄₀ were used for the PDOs less sensitive to the drugs.